Activation of AMPK inhibits Galectin-3-induced pulmonary artery smooth muscle cells proliferation by upregulating hippo signaling effector YAP

Qianqian Zhang,Wenge Li,Yanting Zhu,Qingting Wang,Cui Zhai,Wenhua Shi,Wei Feng,Jian Wang,Xin Yan,Limin Chai,Yuqian Chen,Cong Li,Pengtao Liu,Manxiang Li
DOI: https://doi.org/10.1007/s11010-021-04131-3
IF: 3.842
2021-04-02
Molecular and Cellular Biochemistry
Abstract:Galectin-3(Gal-3) is an effective regulator in the pathological process of pulmonary arterial hypertension (PAH). However, the detailed mechanisms underlying Gal-3 contribution to PAH are not yet entirely clear. The aim of the present study was to explore these issues. Proliferation of rat pulmonary arterial smooth muscle cells (PASMCs) was determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Small interfering RNA (siRNA) was applied to silence the expression of yes-associated protein (YAP) and Forkhead box M1 (FOXM1). The protein expression and phosphorylation were measured by immunoblotting. The subcellular location of YAP was determined using immunoblotting and immunofluorescence. Gal-3-stimulated PASMCs proliferation in a time- and dose-dependent manner, this was accompanied with, YAP upregulation, dephosphorylation, and nucleus translocation. Gal-3 further increased FOXM1 and cyclinD1 expression via YAP activation. Interfering YAP/FOXM1 axis suppressed Gal-3-induced PASMCs proliferation. Activation of AMPK also inhibited Gal-3-triggered cells proliferation by targeting YAP/FOXM1/cyclinD1 pathway. Gal-3 induced PASMCs proliferation by regulating YAP/FOXM1/cyclinD1 signaling cascade, and activation of AMPK targeted on this axis and suppressed Gal-3-stimulated PASMCs proliferation. Our study provides novel therapeutic targets for prevention and treatment of PAH.
cell biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore how Galectin - 3 (Gal - 3) promotes the proliferation of pulmonary artery smooth muscle cells (PASMCs) by regulating the effector protein YAP in the Hippo signaling pathway and its downstream targets FOXM1 and cyclinD1, thereby playing a role in the development of pulmonary artery hypertension (PAH). In addition, the study also explores whether activation of AMPK can inhibit the proliferation of PASMCs by suppressing the Gal - 3 - induced YAP/FOXM1/cyclinD1 signaling axis, providing new perspectives and effective targets for the prevention and treatment of PAH. Specifically, the main research objectives of the paper include: 1. **Clarify the effect of Gal - 3 on the proliferation of PASMCs**: Verify through experiments whether Gal - 3 can promote the proliferation of PASMCs in a dose - and time - dependent manner. 2. **Explore the regulatory mechanism of Gal - 3 on the YAP/FOXM1/cyclinD1 signaling axis**: Analyze whether Gal - 3 promotes the proliferation of PASMCs by up - regulating the expression, dephosphorylation and nuclear translocation of YAP, and subsequently increasing the expressions of FOXM1 and cyclinD1. 3. **Evaluate the inhibitory effect of AMPK activation on Gal - 3 - induced proliferation of PASMCs**: Study whether activation of AMPK (such as using metformin) can inhibit the Gal - 3 - induced YAP/FOXM1/cyclinD1 signaling axis, and then inhibit the proliferation of PASMCs. These research objectives aim to gain an in - depth understanding of the pathological mechanism of PAH and explore possible treatment strategies.